The Treatment-Resistant Depression Map

What treatment-resistant actually means — and what the options look like when first-line treatment hasn't worked.

Treatment-resistant depression has a specific definition in the clinical literature: the persistence of significant depressive symptoms after two or more adequate trials of antidepressant medication. "Adequate" matters — it means a sufficient dose for a sufficient duration (usually six to eight weeks at the target dose). Many people who think they have treatment-resistant depression actually haven’t had an adequate trial yet.

When the trials really have been adequate, the cluster is its own situation. The standard first-line approach (an SSRI, time, hope) has been tried and didn't work, and the next steps are different from what most primary care or general therapy can offer. The treatment options at this point include augmentation strategies (adding a second medication on top of the first), switching medication classes, neurostimulation (TMS, ECT), rapid-acting treatments (ketamine, esketamine), and referral to a depression specialty clinic.

The thing most people don't realize about treatment-resistant depression: most cases respond to one of these next-line options. The major US trials (STAR*D, STEP-BD) found that most patients reach remission with persistent, sequential treatment trials — it just takes more attempts than the average primary care office is set up to manage. The path is real and it usually leads somewhere.

This map shows the cluster — what treatment-resistant depression actually is, what makes a treatment trial "adequate," what the next-line options are, and how to find a specialist who manages this territory. If you’re here because the first medication didn’t work, the next move is usually about finding the right type of clinician for the next attempt, not about giving up on treatment.

Tap any node to read the page on that experience.

Inside this cluster

The Treatment-Resistant Depression Map: a central node labeled Treatment-Resistant Depression connected to 8 elements — two antidepressants tried, the adequate-dose-and-duration test, persistent anhedonia, augmentation strategies, TMS, ketamine/esketamine, ECT, and specialist referral.

Two antidepressants tried — The clinical threshold for "treatment-resistant." Both trials need to have been at adequate dose for adequate duration to count.
Adequate dose + duration — Six to eight weeks at target dose, with reasonable adherence. Many "treatment failures" turn out, on closer review, to be incomplete trials.
Persistent anhedonia — The depression symptom most likely to remain after a partial response. Often the symptom that prompts the treatment-resistant workup in the first place.
Augmentation strategies — Adding a second agent on top of the antidepressant — lithium, an atypical antipsychotic (aripiprazole, brexpiprazole, quetiapine), or thyroid hormone (T3). Each has evidence.
TMS — Transcranial magnetic stimulation. FDA-approved for treatment-resistant depression. Daily sessions for six weeks; response in roughly half of patients who try it.
Ketamine / esketamine — Rapid-acting treatments. Intranasal esketamine is FDA-approved as an augmentation for TRD. Works in hours to days for some patients, not all.
ECT — Electroconvulsive therapy. The single most effective treatment for severe depression. Underused because of stigma; appropriate especially when depression is life-threatening.
Specialist referral — A psychiatrist who manages treatment-resistant depression specifically. Most primary care offices aren't set up to sequence next-line options at this level.

Treatment that works on this cluster

Several lines of treatment have evidence specifically for depression that hasn’t responded to first-line medication. Augmentation with lithium, with an atypical antipsychotic (aripiprazole, brexpiprazole, quetiapine), or with thyroid hormone (T3) all have evidence. Switching antidepressant class — moving from an SSRI to an SNRI, to bupropion, to mirtazapine — works for a meaningful subset. Transcranial magnetic stimulation (TMS) has FDA approval for treatment-resistant depression and works in roughly half of patients who try it. Esketamine (intranasal ketamine) is FDA-approved as an augmentation for treatment-resistant depression and acts within hours to days, not weeks. Electroconvulsive therapy (ECT) remains the most effective single treatment for severe depression and is appropriate especially when the depression is life-threatening. Specialty depression clinics manage these options sequentially in a way most primary care offices can’t.

What people describe

One person describes the first six months. The SSRI was working a little — sleep was better, the worst of the crying spells had eased — but they still couldn’t enjoy anything and still felt tired all the time. Their primary care doctor told them "the medication is working, give it more time." Six months later, nothing more had changed. When they finally got referred to a psychiatrist, the psychiatrist said: this isn’t treatment failure, this is one trial. We have a lot of next moves.

Another describes the TMS course. It was six weeks of daily appointments, each one thirty minutes, nothing dramatic during the sessions. By the end of the third week, they noticed they had laughed at something on TV and that it had landed. They hadn’t laughed at TV in two years. The change was incremental, but for the first time in a long time, it was forward motion. They finished the course in remission for the first time.

Why this cluster matters

Treatment-resistant depression is one of the most under-recognized clusters in mental health, because the most common response to a partially-working first medication is to stay on it and hope for more. Naming the cluster as treatment-resistant unlocks the next-line options that actually move it. The combination of more clinician time, more aggressive sequencing, and access to TMS, ketamine, or ECT is what changes the trajectory. Most cases of treatment-resistant depression respond — it just takes the right type of care.

How this differs from adjacent clusters

Treatment-resistant depression is often confused with depression that hasn’t been adequately treated. The distinction is in the definition of "adequate." An adequate antidepressant trial is the right dose, for the right duration (usually 6-8 weeks at target dose), with the right adherence. If any of those wasn’t met, the cluster isn’t treatment-resistant; it’s incompletely treated, and the next step is finishing the trial properly.

Treatment-resistant depression is also sometimes confused with depression that's actually a different diagnosis. Bipolar depression looks identical to unipolar depression but responds to mood stabilizers, not SSRIs. Depression in the context of substance use, thyroid dysfunction, or other medical conditions may not respond to standard antidepressants until the underlying issue is addressed. A second evaluation — looking for missed diagnoses — is part of the treatment-resistant workup.

Finally, treatment-resistant depression isn't the same as depression that's incompletely managed because of side effects. If the first medication worked but you stopped it because of side effects, the cluster is "intolerable side effects with one medication," not treatment-resistant. The path is different: try a different medication class with a different side effect profile, not jump to TMS or ketamine.

Sources▸

The Knowledge Path